Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status

Abstract

AUTHOR CONTRIBUTIONS Marina Stasenko: Conception and design; analysis and interpretation of data; drafting of article; revising article critically for important intellectual content; final approval of version to be published; agrees to be accountable for all aspects of the work. Paulina Cybulska: Analysis and interpretation of data; drafting of article; final approval of version to be published; agrees to be accountable for all aspects of the work. Noah Feit: Analysis and interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Vicky Makker: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Jason Konner: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Roisin E. O'Cearbhaill: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Kaled M. Alektiar: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Kathryn Beal: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Ginger J. Gardner: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Kara C. Long Roche: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Yukio Sonoda: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Dennis S. Chi: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Oliver Zivanovic: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Mario M. Leitao Jr.: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. Karen A. Cadoo: Interpretation of data; revising article critically; final approval of version to be published; agrees to be accountable for all aspects of the work. William P. Tew: Conception and design; analysis and interpretation of data; drafting of article; revising article critically for important intellectual content; final approval of version to be published; agrees to be accountable for all aspects of the work.

Extraordinary Pattern with Brain Metastasis of Ovarian Cancer with Five Cases: Survival Impact of Cranial Metastesectomy. Do or Not To Do?

“…The average figure of 2.55% found in our literature review is consistent with the most recent post mortem review with the incidence of 2.1% (7 out of 340 cases). However, since most reports are from clinical studies and very few postmortem studies have been performed, it is possible that the actual incidence of brain metastasis from ovarian cancer is higher since brain imaging is not a routine component of follow up for patients with ovarian cancer to detect asymptomatic lesions [3,[8][9][10].…”

Metastatic epithelial ovarian cancer to Meckel’s cave with leptomeningeal spread at time of diagnosis

“…First, this is the only published report of ovarian cancer with metastatic spread to Meckel’s cave, which presented with symptoms consistent with trigeminal nerve disruption. The average time between diagnosis of ovarian cancer and metastasis to the brain has been reported as roughly 31 months ( Stasenko et al, 2019 ). In this case, brain metastasis with leptomeningeal spread occurred simultaneously with the primary diagnosis of cancer, something that has rarely been described with less than a handful of reported cases in current literature ( Izquierdo et al, 1992 , Matsunami et al, 1999 ).…”

“…Studies have reported that BRCA1/2 status and hormone receptor status of EOC have possible implications with the development of brain lesions. In a 2018 retrospective study of 3,649 EOC patients, Stasenko et al found that patients with BRCA1/2 pathogenic variants were more likely to have isolated brain metastasis as compared to BRCA1/2 wild-type patients (48% vs. 19%, p = 0.02) ( Stasenko et al, 2019 ). In a 2017 retrospective study, Mittica et al demonstrated the risk of developing brain metastasis appeared 9.5 times greater in patients with androgen receptor (AR)-negative primary ovarian cancer as compared to AR-positive (p = 0.013) ( Mittica et al, 2017 ).…”

Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

“…A recent study [64] explored the characteristics of 96 OC women who developed BMs, according to BRCA status (21 BRCA mutations carriers and 63 BRCA wild type patients). BRCA mutations carriers showed a better OS (29 months vs. 9 months), with an HR of 0.53 after stratifying for the presence of systemic disease (95% CI: 0.25-1.11, p = 0.09).…”